Drugs / VXA-GII.4-NS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05626803 | Jan → Oct 2023 | norovirus infectious disease | Vaxart | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-GII.4-NS | “This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS...” NCT05626803 ↗ |
| Modality | Vaccine | “two monovalent Norovirus (NoV) oral tableted vaccine candidates” NCT05626803 ↗ |